Endocrine Society lauds Novo Nordisk for commitment to affordable insulin

May 10, 2017

Contact: Aaron Lohr
Chief Communications Officer
Phone: 202.971.3654
alohr@endocrine.org
Contact: Jenni Glenn Gingery
Associate Director, Communications and Media Relations
Phone: 202.971.3655
jgingery@endocrine.org

Novo Nordisk’s partnership with CVS Caremark designed to help patients with high out-of-pocket costs

Washington, DC - The Endocrine Society applauded Novo Nordisk’s recent partnership with CVS Caremark on their new program Reduced Rx™, a prescription savings program that offers discounts on certain medications. Through the partnership, which goes into effect today, patients facing high out-of-pocket costs for insulin will be able to purchase human insulin, Novolin®, for $25 per 10 mL vial, a potential savings of $100 for cash-paying patients.

People with type 1 diabetes are unable to produce their own insulin and need insulin treatment to maintain their glucose control. People with the more common type 2 diabetes do not produce enough insulin or their bodies cannot use it efficiently. These individuals may need insulin treatment as well. Many people with diabetes depend on insulin, yet increasing prices create a dangerous barrier to access this critical therapy.

The Society is encouraged by Novo Nordisk’s efforts to increase affordable access to this life-saving therapy and will continue to strongly advocate for people with diabetes who depend on insulin to treat their condition.

The Society believes that with greater transparency across the insulin supply chain, stakeholders can work together to make drug pricing more predictable, reduce out-of-pocket costs, and help patients and providers maintain access to affordable, patient-centered therapies.

###

Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.

The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.